中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
23期
37-38
,共2页
前列地尔%依达拉奉%脑梗死%疗效
前列地爾%依達拉奉%腦梗死%療效
전렬지이%의체랍봉%뇌경사%료효
Alprostadil%Edaravone%Infarction%Efficacy
目的 探讨前列地尔联合依达拉奉治疗脑梗死的临床疗效及可行性.方法 将78例脑梗死患者随机分为实验组和对照组,对照组给予复方丹参注射液、胞二磷胆碱注射液常规治疗,实验组在此基础上给予前列地尔和依达拉奉治疗.比较两组神经功能缺损评分(NDS)、日常生活能力量表(ADL)及临床治疗效果.结果 两组治疗前NDS和ADL评分比较差异无统计学意义(P＞0.05),治疗14 d后两指标较治疗前均明显改善(P＜0.05),但实验组两指标改善幅度明显大于对照组(P＜0.05).实验组治疗14 d后总有效率为95.0％,远高于对照组的76.3％ (P ＜0.05),观察组并发症3例,少于对照组的7例(P＜0.05).结论 前列地尔联合依达拉奉治疗脑梗死疗效确切,能有效缓解神经功能缺损程度,改善日常生活能力.
目的 探討前列地爾聯閤依達拉奉治療腦梗死的臨床療效及可行性.方法 將78例腦梗死患者隨機分為實驗組和對照組,對照組給予複方丹參註射液、胞二燐膽堿註射液常規治療,實驗組在此基礎上給予前列地爾和依達拉奉治療.比較兩組神經功能缺損評分(NDS)、日常生活能力量錶(ADL)及臨床治療效果.結果 兩組治療前NDS和ADL評分比較差異無統計學意義(P＞0.05),治療14 d後兩指標較治療前均明顯改善(P＜0.05),但實驗組兩指標改善幅度明顯大于對照組(P＜0.05).實驗組治療14 d後總有效率為95.0％,遠高于對照組的76.3％ (P ＜0.05),觀察組併髮癥3例,少于對照組的7例(P＜0.05).結論 前列地爾聯閤依達拉奉治療腦梗死療效確切,能有效緩解神經功能缺損程度,改善日常生活能力.
목적 탐토전렬지이연합의체랍봉치료뇌경사적림상료효급가행성.방법 장78례뇌경사환자수궤분위실험조화대조조,대조조급여복방단삼주사액、포이린담감주사액상규치료,실험조재차기출상급여전렬지이화의체랍봉치료.비교량조신경공능결손평분(NDS)、일상생활능역량표(ADL)급림상치료효과.결과 량조치료전NDS화ADL평분비교차이무통계학의의(P＞0.05),치료14 d후량지표교치료전균명현개선(P＜0.05),단실험조량지표개선폭도명현대우대조조(P＜0.05).실험조치료14 d후총유효솔위95.0％,원고우대조조적76.3％ (P ＜0.05),관찰조병발증3례,소우대조조적7례(P＜0.05).결론 전렬지이연합의체랍봉치료뇌경사료효학절,능유효완해신경공능결손정도,개선일상생활능력.
Objective To investigate the clinical efficacy and feasibility of alprostaudil and edaravone on cerebral infarction.Methods Seventy-eight cases of cerebral infarction were randomly divided into experimental group and control group.The patients of control group were treated with compound Danshen injection and citicoline injection conventional therapy.On this basis,the patients of experimental group were given alprostadil and edaravone.Then,the neurological deficit score(NDS),ADL and clinical effect of the two groups were compared.Results Before treatment,the NDS and ADL scores of the two groups had no significant difference (P ＞ 0.05),after 14 days of treatment,the indicators of two groups significantly improved (P ＜ 0.05),but two indicators of magnitude improvement in the experimental group patients were significantly greater than the control group (P ＜ 0.05).After 14 days of treatment,the total effective rate of the experimental group was 95.0％,it was far higher than the control group(76.3％) (P ＜ 0.05).The experimental group had 3 cases of patients with complications,less than that in the control group(7 cases) (P ＜ 0.05).Conclusions Alprostadil combine with edaravone has exact clinical efficacy on cerebral infarction.It can effectively alleviate the degree of neurological deficit and improve the ability of daily lives.
